2 hours HC Wainwright Reaffirms “Buy” Rating for Ovid Therapeutics (NASDAQ:OVID) MarketBeat
HC Wainwright restated a “buy” rating and issued a $3.00 target price on shares of Ovid Therapeutics in a research note on Monday.
HC Wainwright restated a “buy” rating and issued a $3.00 target price on shares of Ovid Therapeutics in a research note on Monday.